ArticleFrontiers in medicine2026
Metastatic organ distribution characteristics and prognosis in patients with non-small cell lung cancer.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Non-small cell lung cancer (NSCLC) is often diagnosed at advanced stages, with distant metastasis being the leading cause of death. However, the distribution patterns of metastatic organs and their prognostic impact remain unclear. This study aimed to characterize the distribution of metastatic organs and evaluate their prognostic significance in patients with metastatic NSCLC. Methods: This retrospective study included 305 patients with metastatic NSCLC diagnosed at our institution between 1 January 2022 and 1 January 2026. Patients were categorized into the single-organ metastasis (SOM) group ( Results: The most common metastatic site was the bone in both the SOM (40.9%) and MOM (82.2%) groups. Patients in the MOM group exhibited significantly worse OS than those in the SOM group (median OS: 3.22 vs. 8.22 months, log-rank test Conclusion: Multiple-organ metastasis independently predicts poorer prognosis. In patients with SOM, preliminary evidence suggests that adrenal gland involvement may be associated with worse survival than bone or lung metastases, whereas no significant differences were observed among the other sites. These findings highlight the importance of assessing both the extent and distribution of metastatic involvement for risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.